biostudies-literatureYau TCCIntramural NIH HHS2405-2413https://www.ebi.ac.uk/biostudies/studies/S-EPMC5420486biostudies-literatureUnknown23(10)<b>Purpose:</b> This phase I/II single-arm study evaluated the safety, pharmacokinetics, pharmacodynamics, and activity of foretinib, an oral multikinase inhibitor of MET, ROS, RON, AXL, TIE-2, and VEGFR2, in the first-line setting in advanced hepatocellular carcinoma patients.<b>Experimental Design:</b> In the phase I part, advanced hepatocellular carcinoma patients were dose escalated on foretinib (30-60 mg) every day using the standard 3+3 design. Once the maximum tolerated dose (MTD) was determined, an additional 32 patients were dosed at the MTD in the phase II expansion cohort for assessment of efficacy and safety. Exploratory analyses were conducted to assess potential biomarkers that might correlate with clinical efficacy and survival.<b>Results:</b> The MTD of foretinib was establClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.PMC5420486Z01 BC011124Gagnon RCYen CJCox DSSukeepaisarnjaroen WLausoontornsiri WBottaro DPYau TCCLiu YRaffensperger KELencioni RPoon RTPChao YChen PJKallender HKulkarni DACamp ASanpajit TOttesen LHfalseA Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.<b>Purpose:</b> This phase I/II single-arm study evaluated the safety, pharmacokinetics, pharmacodynamics, and activity of foretinib, an oral multikinase inhibitor of MET, ROS, RON, AXL, TIE-2, and VEGFR2, in the first-line setting in advanced hepatocellular carcinoma patients.<b>Experimental Design:</b> In the phase I part, advanced hepatocellular carcinoma patients were dose escalated on foretinib (30-60 mg) every day using the standard 3+3 design. Once the maximum tolerated dose (MTD) was determined, an additional 32 patients were dosed at the MTD in the phase II expansion cohort for assessment of efficacy and safety. Exploratory analyses were conducted to assess potential biomarkers that might correlate with clinical efficacy and survival.<b>Results:</b> The MTD of foretinib was establ2017-01-01T00:00:00Z2017 May2026-05-03T16:39:25.595Z2019-03-26T23:37:08ZS-EPMC54204862782160510.1158/1078-0432.ccr-16-178910.1158/1078-0432.CCR-16-1789